Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains.
In addition to providing mechanical stability, growing evidence suggests that surfactant lipid components can modulate inflammatory responses in the lung. However, little is known of the molecular mechanisms involved in the immunomodulatory action of surfactant lipids. This study investigates the effect of the lipid-rich surfactant preparations Survanta, Curosurf, and the major surfactant phospholipid dipalmitoylphosphatidylcholine (DPPC) on interleukin-8 (IL-8) gene and protein expression in human A549 lung epithelial cells using immunoassay and PCR techniques. To examine potential mechanisms of the surfactant lipid effects, Toll-like receptor 4 (TLR4) expression was analyzed by flow cytometry, and membrane lipid raft domains were separated by density gradient ultracentrifugation and analyzed by immunoblotting with anti-TLR4 antibody. The lipid-rich surfactant preparations Survanta, Curosurf, and DPPC, at physiological concentrations, significantly downregulated lipopolysaccharide (LPS)-induced IL-8 expression in A549 cells both at the mRNA and protein levels. The surfactant preparations did not affect the cell surface expression of TLR4 or the binding of LPS to the cells. However, LPS treatment induced translocation of TLR4 into membrane lipid raft microdomains, and this translocation was inhibited by incubation of the cells with the surfactant lipid. This study provides important mechanistic details of the immune-modulating action of pulmonary surfactant lipids.
Abate
Wondwossen
W
Centre for Research in Biomedicine, Faculty of Health and Life Science, University of the West of England, Bristol, UK.
Alghaithy
Abdulaziz A
AA
Parton
Joan
J
Jones
Kenneth P
KP
Jackson
Simon K
SK
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000494:pharmacology; D001688:Biological Products / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D015536:Down-Regulation / Q000187:drug effects; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008168:Lung / Q000166:cytology*; D021962:Membrane Microdomains / Q000187:drug effects* / Q000378:metabolism; D010743:Phospholipids / Q000494:pharmacology; D021381:Protein Transport / Q000187:drug effects; D011663:Pulmonary Surfactants / Q000494:pharmacology*; D051197:Toll-Like Receptor 4 / Q000378:metabolism*
D001688:Biological Products; D016209:Interleukin-8; D008070:Lipopolysaccharides; D010743:Phospholipids; D011663:Pulmonary Surfactants; D051197:Toll-Like Receptor 4; D015060:1,2-Dipalmitoylphosphatidylcholine; C068291:poractant alfa; C072197:beractant